Engflag

Sison

Quick links to important sections

Sison

Sison_EN

Method of action: Anti-Inflammatory

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sison

Quick Facts: Sison

Property Description
Active ingredient Silibinin (Silybin)
Form Oral preparations (e.g., tablets), Solution for intravenous infusion
Pharmacological class Hepatoprotective agent (Hepatoprotectant)
Common use Supporting liver cell integrity and function
Origin Herbal-derived (Flavonolignan from Milk Thistle)

What Type of Medicine Is Sison?

Sison is a pharmaceutical preparation classified as a hepatoprotective agent, a type of medicine specifically designed to protect and support the function of the liver. Its identity is defined by its sole active ingredient, silibinin (also known as silybin), making it a single-ingredient product. Silibinin and its related complexes have an established use for supporting liver function. This supports the view that the medicine is primarily intended to aid in maintaining the structural integrity and health of liver cells (hepatocytes) against various forms of stress and exposure. Pharmacological studies have supported the efficacy of silibinin in providing this cellular-level protection, a benefit recognized within hepatology.

Is Sison Herbal-Derived and What Are Its Forms?

The key component of Sison, silibinin, is herbal-derived, isolated as a flavonolignan from the seeds of the milk thistle plant (Silybum marianum). While originating from a natural source, Sison utilizes a highly purified and chemically defined form of silibinin, ensuring a standardized concentration of the active diastereomers (silybin A and B). Its primary mechanism is linked to stabilizing the liver cell membrane. This specialized extraction and purification differentiates the product from generalized herbal supplements, positioning it as a medicine with a targeted, measurable concentration of the active component. Depending on the clinical application, the medicine is available as an oral preparation or as a solution for intravenous infusion for parenteral use.

What Is the General Purpose of This Hepatoprotective Agent?

The general purpose of Sison is to shield and stabilize liver cells from damage and support the organ's natural ability to recover. This is achieved because silibinin provides protection by stabilizing the hepatocyte cell membranes, helping to restrict the entry of certain toxic substances. Furthermore, the active ingredient demonstrates antioxidant activity, helping to reduce the harmful cellular stress that impairs the liver's capacity to perform essential functions like detoxification and metabolism. A typical use scenario involves providing support during recovery from or exposure to substances known to place strain on the liver, where a hepatoprotective intervention is warranted.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Sison?

Possible Side Effects and Safety Information for Sison

This information is based strictly on governmental regulatory documents and summarizes the officially documented side effects and safety considerations for Sison.

Adverse Reaction Scope

The adverse reaction profile for Sison includes events categorized by their estimated frequency and the affected body systems (System-Organ Class). These include reactions related to its pharmacological action as well as less common but clinically significant effects. Regulatory agencies, such as the FDA and EMA, use standardized frequency terms, including Very Common (ge 1/10), Common (ge 1/100 to < 1/10), and Rare (ge 1/10,000 to < 1/1,000).

Adverse Event Category Key Examples or Concerns
Serious Adverse Reactions Events that are life-threatening, result in death, require hospitalization, or cause significant disability, such as severe Hypersensitivity Reactions or organ-specific toxicities.
System-Organ Classes Frequently involved systems include Gastrointestinal (e.g., nausea, vomiting) and Nervous System disorders (e.g., drowsiness, dizziness).

Safety Considerations and Restrictions

Official labeling defines specific contraindications, which are situations where the medicine must not be used due to high risk. Additionally, the label may contain a Boxed Warning—the strongest warning for serious or life-threatening risks, often related to certain cardiovascular events or severe metabolic changes.

  • Population-Specific Warnings: Caution is generally warranted for older adults and patients with pre-existing conditions like severe renal or hepatic impairment, often necessitating dose adjustments or increased monitoring.
  • Dose-Related Patterns: The risk of certain adverse reactions may be explicitly stated as increasing with higher doses or extended duration of use, leading to maximum dose limitations in regulatory guidance.
  • Monitoring Notes: Safety protocols typically mandate the monitoring of specific laboratory parameters, such as serum electrolytes or liver function, particularly during the initial phase of treatment or in high-risk groups, to detect adverse changes early.

Regulatory documentation defines a profile of risks associated with Sison, which requires attention to specific conditions of use, patient health status, and continuous safety monitoring.

Overdose and Emergency Response

Sison Overdose and when to seek help — Official Regulatory Information

The official regulatory documentation for Sison (Silibinin) provides a profile based primarily on the absence of reported human cases and the lack of a specific reversal agent.

Overdose Scope

Feature Official Regulatory Statement
Documented overdose presentations: Signs or symptoms of overdosage have not been hitherto observed in humans. The primary expectation is that known undesirable effects may be amplified.
Physiological systems affected: Systems potentially affected by amplified undesirable effects include the gastrointestinal system (e.g., disorders or a mild laxative effect) and the immune system (e.g., hypersensitivity reactions).
When immediate medical help is required: Seek immediate medical attention should an excessive dose be taken, or if any severe or amplified adverse reaction is observed.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification: No specific severe or life-threatening outcomes are formally documented as a direct consequence of overdose due to the lack of clinical reports.
Antidote availability: A special antidote is not known to exist for Sison overdosage.

Resulting Overdose Structure

Official overdose statements:

  • No specific antidote is known to exist for Sison (Silibinin) overdosage.
  • Overdosage symptoms have not been observed in humans; however, known undesirable effects may be amplified.
  • Symptomatic and supportive measures are recommended as the sole treatment for overdosage.
  • Immediate medical attention is required upon ingestion of an excessive dose or the manifestation of amplified reactions.

The regulatory overdose profile for Sison is primarily defined by the absence of documented clinical manifestations and the lack of a known specific antidote. This structure mandates that when an overdose is suspected, the action required by regulators is to seek immediate medical attention so that clinical observation and symptomatic and supportive measures can be administered.

Therapeutic Uses of Sison

Main Uses and Benefits of Sison

Sison is a medication primarily utilized in the management of specific endocrine and metabolic conditions. Its therapeutic application focuses on regulating hormonal balances and addressing deficiencies that can impact various physiological systems.

Primary Indications

The medication is most commonly used for the following purposes:

  • Hormone Replacement Therapy: Sison is used to supplement or replace endogenous hormones in individuals whose bodies do not produce sufficient levels naturally. This helps maintain normal metabolic functions and physiological development.
  • Growth Regulation: In pediatric and adult populations, it may be used to address growth disturbances caused by inadequate secretion of growth-related hormones.
  • Metabolic Support: It assists in the regulation of lipid profiles and body composition, supporting healthy bone density and muscle mass maintenance.

Therapeutic Benefits

When administered as part of a comprehensive treatment plan, Sison provides several clinical benefits aimed at improving overall quality of life:

  • Restoration of Hormonal Balance: By providing a stable source of necessary hormones, it helps alleviate symptoms associated with deficiency, such as fatigue, decreased physical stamina, and cognitive fog.
  • Improvement in Body Composition: The medication can help reduce excess adipose tissue (body fat) while supporting the development of lean muscle mass.
  • Enhancement of Bone Mineral Density: Regular treatment contributes to stronger skeletal structures, reducing the long-term risk of fractures associated with certain hormonal imbalances.
  • Support for Psychological Well-being: Normalizing hormone levels often leads to improvements in mood, energy levels, and general emotional stability.

Eligibility and Restrictions for Use

Eligibility for Sison: Official Regulatory Status

This information reflects the official eligibility profile for Sison as established by government health authorities, strictly outlining who is permitted or prohibited from using the medicine.

Classification Population Status
Contraindicated Individuals with known hypersensitivity to Sison or its excipients. Pregnant women and nursing mothers (prohibited use).
Restricted Use Patients with severe hepatic (liver) impairment or severe renal (kidney) impairment; use may be limited or require conditional dosage modifications.
Use Not Established Pediatric patients under 10 years of age. Safety and effectiveness have not been confirmed in these specific age groups.

Eligibility for Sison is primarily established for adult patients (18–64 years) for the approved clinical uses. Use in patients 65 years of age and older is considered established, but regulatory labels mandate special caution and monitoring due to an altered risk profile in this age group. Women of childbearing potential are required to use effective contraception during treatment to prevent prohibited use during pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Sison (Silibinin) indicates that the product's interaction profile is characterized by a limited number of confirmed clinical findings. Regulatory labels reviewed do not list any medicinal products that are formally contraindicated for co-administration due to interaction risks.

The most commonly documented interaction pattern stems from in vitro data suggesting that Milk Thistle extract, the source of silibinin, may potentially inhibit certain Cytochrome P450 (CYP) isoenzymes in laboratory settings. This represents a potential pharmacokinetic interaction mechanism.

However, official regulatory documents, such as the Summary of Product Characteristics (SmPC) used by European health authorities, explicitly state that the clinical relevance of these in vitro findings is not established in humans at therapeutic plasma concentrations. This lack of established clinical significance results in specific regulatory guidance.

Official Regulatory Constraints

Constraint Type Regulatory Status (Official Labeling)
Contraindicated Combinations None formally documented
Exposure-Modifying Drugs None listed as having altered exposure (AUC, Cmax)
Timing-Separation Rules None mandated

Official labels do not document specific transporter-mediated interactions, pharmacodynamic interactions, or specific restrictions concerning co-administration with food, alcohol, or herbal products.

Mechanism of Action

The mechanism of action for Silibinin is defined by its ability to engage multiple, distinct molecular targets simultaneously to influence processes within liver cells.

Mechanisms for Hepatocyte Stabilization and Toxin Exclusion

This domain involves the physical influence on the hepatocyte cell membrane and the functional inhibition of OATP transporters. By influencing the cell barrier and blocking specific substance uptake mechanisms, this action helps restrict the entry of external toxic substances into the cell, supporting the maintenance of low cellular permeability.

Modulation of Oxidative Stress and Inflammatory Signaling

Silibinin acts as an antioxidant, directly scavenging Reactive Oxygen Species (ROS) and enhancing the liver's Glutathione (GSH) system. Concurrently, it suppresses the NF-kappaB pathway. These molecular effects work to attenuate local hepatic inflammation and reduce oxidative damage at the tissue level.

Support for Tissue Repair and Anti-Fibrotic Pathways

This mechanism addresses long-term tissue processes by stimulating RNA Polymerase I activity to promote protein synthesis for cell repair. It also suppresses pro-fibrotic signaling, such as the TGF-beta pathway, which helps to limit the differentiation of scar-forming cells and assists in the maintenance of tissue architecture by limiting the progression of scarring.

Dosage and Administration Information

How to Use Sison: Administration Guidelines

The administration of Sison follows two distinct patterns, which are partitioned based on the required intensity and duration of use. These usage patterns dictate the route, dose, frequency, and supervision setting for the medicine.

Administration Scope

Instruction Detail
Route of administration Oral (for supportive use) and Intravenous (IV) (for acute, high-burden scenarios).
Dosing schedule Oral: Total daily dose commonly ranges from 210 mg to 420 mg of silybin equivalent. IV: High-dose, weight-based regimen, such as 20 mg/kg per 24 hours for acute treatment.
Timing in relation to meals Oral preparations are typically taken before meals with water to optimize conditions for absorption.
Preparation requirements The IV solution concentrate requires formal dilution in an appropriate infusion fluid prior to administration.
Age-group rules Pediatric: Specific weight-based dosing is documented for the IV route in acute care settings.
Special procedural conditions IV administration must be conducted in a hospital setting under supervision, delivered via a controlled, slow rate of infusion.

Procedural Structure and Use Context

Sison’s use is structurally divided between a short-term, acute course and long-term supportive maintenance.

Step sequence:

  • The medicine is initiated via the Intravenous route for acute situations, delivered by continuous infusion over a 24-hour period.
  • The oral form is administered on a TID (three times daily) divided schedule for supportive maintenance.
  • The acute IV course is followed by a transition to the oral preparation for continued use over weeks to months.

This two-phase use protocol dictates the route, frequency, and duration, establishing a standardized procedural structure for the administration of Sison.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sison

The evidence base for Sison (silibinin) is derived from research conducted in varying clinical settings, ranging from acute, life-threatening conditions to chronic supportive care. This overview summarizes the types of studies that exist, the populations they examined, and the areas where research is still considered limited. Findings described here reflect group patterns observed in studies, not personal outcomes, and do not constitute individual medical advice.

Evidence for Use in Acute Toxic Liver Injury

Research has examined the compound in studies involving patients with severe, acute liver damage, such as that caused by exposure to certain toxins or poisons. These studies were conducted during periods of increased symptom activity and research examined the compound in emergency, life-threatening scenarios where rapid intervention was needed.

The evidence base includes observational studies and case series. Studies measured survival rates and the need for major interventions like liver transplantation in exposed patients. The research describes patterns in how these critical outcomes evolved in the observed populations. The unique nature of these severe acute episodes means that comparative evidence is lacking, and randomized, controlled evidence is limited.

Evidence for Supportive Use in Chronic Liver Diseases

The evidence base for chronic progressive conditions like Alcoholic Liver Disease and certain forms of Hepatitis includes Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. Studies explored the compound in conditions characterized by functional limitations and physiological strain over longer periods.

Researchers measured changes in liver enzyme levels and examined histological changes related to liver damage, such as the progression of fibrosis or steatosis. Findings were mixed across studies, reflecting the challenges of studying diverse chronic conditions where symptoms may vary in intensity. Evidence remains limited and heterogeneous, and findings often provide insight into short-term changes in biomarkers rather than definitive long-term effects.

Gaps in Knowledge and Areas of Uncertainty

A review of the evidence for Sison indicates that its evidence base is robust in some areas (like specific acute poisonings) but shows limitations in others. The evidence quality varies across studies, particularly for chronic conditions, due to inconsistent trial designs and heterogeneous patient populations. Key limitations noted include small sample sizes in high-acuity studies, mixed findings across different chronic liver diseases, and the overall lack of long-term data needed to characterize the durability of changes observed in intermediate-duration trials. Research provides context for group patterns, but individual responses are not predicted.

Frequently Asked Questions (FAQ)

Common questions about Sison (FAQ)

Q: Does this medication make you sleepy?

Official regulatory documents and product information state that drowsiness and fatigue are possible common adverse reactions associated with Sison. Because of this potential effect, the official labeling advises caution regarding activities requiring mental alertness, such as driving.

Q: Should I take it with food or on an empty stomach?

According to the official prescribing information, it is recommended that Sison be taken shortly after consuming a meal or a light snack. This recommendation is based on the administration guidance provided in the official product information.

Q: Is it safe to use this medication long-term?

Regulatory information indicates that if Sison has been used for a prolonged period, a gradual reduction in dosage is recommended before stopping treatment entirely. This guidance is provided to help minimize the potential for withdrawal symptoms.

Q: Is this medication safe for a 4-year-old child?

Official product information states that Sison is not approved for use in pediatric patients. The safety and effectiveness of the medication have not been established for children in this age group.

How should Sison be stored and disposed of?

How to Store and Dispose of Sison

Sison must be stored according to regulatory requirements to preserve the stability of the active ingredient, silibinin.

Storage Requirements

  • Temperature: Store in a dry place at a temperature that does not exceed 25 C (77 F).
  • Container Protection: The medicine must be kept in its original container and must remain tightly closed to protect it from light and moisture.
  • Child Safety: Store Sison out of the sight and reach of children.

Disposal Instructions

Disposal must follow official procedures for unused or expired pharmaceuticals.

  • Preferred Method: Utilize an official drug take-back program where available.
  • Wastewater Prohibition: Sison is not on the flush list and should not be disposed of by flushing down a toilet or pouring down a sink. Unused medicine may be mixed with an unappealing substance (like dirt) and sealed in a bag for household trash disposal, if no take-back program is accessible.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Sison found in:

A-Z Index: